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The Down syndrome critical region 1 (DSCR1) gene is present in the region of human chromosome 21 and the syntenic region of mouse
chromosome 16, trisomy of which is associated with congenital heart defects observed in Down syndrome. DSCR1 encodes a regulatory
protein in the calcineurin/NFAT signal transduction pathway. During valvuloseptal development in the heart, DSCR1 is expressed in the
endocardium of the developing atrioventricular and semilunar valves, the muscular interventricular septum, and the ventricular myocardium.
Human DSCR1 contains an NFAT-rich calcineurin-responsive element adjacent to exon 4. Transgenic mice generated with a homologous
regulatory region of the mouse DSCR1 gene linked to lacZ (DSCR1(e4)/lacZ) show gene activation in the endocardium of the developing
valves and aorticopulmonary septum of the heart, recapitulating a specific subdomain of endogenous DSCR1 cardiac expression. DSCR1(e4)/
lacZ expression in the developing valve endocardium colocalizes with NFATc1 and, endocardial DSCR1(e4)/lacZ, is notably reduced or absent
in NFATc1/ embryos. Furthermore, expression of the endogenous DSCR1(e4) isoform is decreased in the outflow tract of NFATc1/ hearts,
and the DSCR1(e4) intragenic element is trans-activated by NFATc1 in cell culture. In trisomy 16 (Ts16) mice, expression of endogenous
DSCR1 and DSCR1(e4)/lacZ colocalizes with anomalous valvuloseptal development, and transgenic Ts16 hearts have increased h-
galactosidase activity. DSCR1 and DSCR1(e4)/lacZ also are expressed in other organ systems affected by trisomy 16 in mice or trisomy 21 in
humans including the brain, eye, ear, face, and limbs. Together, these results show that DSCR1(e4) expression in the developing valve
endocardium is dependent on NFATc1 and support a role for DSCR1 in normal cardiac valvuloseptal formation as well as the abnormal
development of several organ systems affected in individuals with Down syndrome.
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(MCIP1), ADAPT78, or calcipressin, encodes a regulatoryIntroduction
The Down Syndrome Critical Region 1 (DSCR1) gene,
located at position 21q22.12 on human chromosome 21, is
in the genetic interval associated with Down syndrome
congenital heart defects (Fuentes et al., 1995; Korenberg et
al., 1994). The mouse DSCR1 gene is in a syntenic region
of murine chromosome 16 and is expressed in the devel-
oping mouse heart, brain, and central nervous system
(Casas et al., 2001; Epstein et al., 1985; Fuentes et al.,
1997; Mural et al., 2002; Vega et al., 2003). DSCR1, also
known as modulatory calcineurin-interacting protein 10012-1606/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2003.10.036
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E-mail address: yutzey@chmcc.org (K.E. Yutzey).protein in the calcineurin/NFAT signal transduction path-
way that binds to calcineurin to regulate its phosphatase
activity (Ermak et al., 2001; Fuentes et al., 2000; Roth-
ermel et al., 2000). The human DSCR1 gene has four
alternative first exons and multiple splice variants (Ermak
et al., 2002). An intragenic promoter adjacent to exon 4,
which is thought to regulate expression of the DSCR1(e4)
splice isoform, is responsive to increased calcineurin
signaling, thereby creating a potential feedback regulatory
loop (Yang et al., 2000). Calcineurin signaling through the
NFAT family of transcription factors regulates gene ex-
pression in response to elevated Ca2+ levels in the heart,
brain, and immune systems (Crabtree and Olson, 2002;
Molkentin et al., 1998). Evidence for the importance of the
calcineurin/NFAT signaling pathway in embryonic heart
development is provided by mice deficient in NFATc1
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Pompa et al., 1998; Ranger et al., 1998). Although initial
endocardial cushion formation occurs in NFATc1/ em-
bryos, mature semilunar valves are absent and develop-
ment of the AV valves and interventricular septum is
affected (de la Pompa et al., 1998; Ranger et al., 1998).
Still, the molecular mechanism(s) by which NFATc1 reg-
ulates valvuloseptal development and its relationship to
other calcineurin regulatory proteins including DSCR1
remain undefined.
Mice trisomic for chromosome 16 (Ts16) are a murine
model for Down syndrome and have a high incidence of
congenital heart defects as well as abnormalities in the brain,
sensory organs, and skull (Hiltgen et al., 1996; Kola and
Hertzog, 1998; Ludwig et al., 1997; Miyabara et al., 1982;
Webb et al., 1996). Ts16 mice exhibit high frequency of atrial
and ventricular septal defects at late gestation which arise
from malalignment of the heart and abnormal endocardial
cushion formation early in development (Hiltgen et al., 1996;
Webb et al., 1996, 1997, 1999). The high incidence of cardiac
malformations in these mice supports the premise that valvu-
loseptal development is affected by trisomy of genes on
chromosome 16 (Webb et al., 1997). Mouse orthologues
have been identified for many of the approximately 200
genes on human chromosome 21; however, the molecular
mechanisms by which candidate genes contribute to the
cardiac malformations associated with mouse Ts16 or human
Ts21 have not been established (Gitton et al., 2002; Hattori et
al., 2000; Reymond et al., 2002).
The embryonic expression of mouse DSCR1 was ex-
amined during critical stages of valvuloseptal development.
Expression of the murine DSCR1(e4) NFAT-rich intragenic
regulatory element was assessed during normal embryo-
genesis as well as in mice with cardiac valvuloseptal
defects as a result of Ts16 or loss of NFATc1. Transgenic
mice generated with the NFAT-rich DSCR1(e4) promoter
linked to a lacZ reporter gene show expression in the
developing valvuloseptal endocardium in addition to other
structures affected in human Down syndrome. Expression
of the DSCR1(e4)/lacZ transgene in the developing valves
colocalizes with a subset of endocardial cells expressing
NFATc1, and the mouse DSCR1(e4) intragenic promoter
element is activated by NFATc1 in cell culture. Loss of
NFATc1 in homozygous null gene targeted mice results in
a marked reduction or complete absence of endocardial
DSCR1(e4)/lacZ expression, as well as decreased expres-
sion of the endogenous calcineurin-responsive DSCR1(e4)
transcript. Endogenous DSCR1 and DSCR1(e4)/lacZ trans-
gene expression in Ts16 mice colocalizes with anomalous
valvuloseptal development in the heart and craniofacial
and limb structures affected with trisomy 16 in mice or
trisomy 21 in humans. Together, these studies support a
regulatory role for NFATc1 and DSCR1 in normal valvu-
loseptal development and reinforce the association of
DSCR1 with Down syndrome-related developmental
anomalies.Materials and methods
Isolation of the mouse DSCR1 intragenic exon 4 (e4)
regulatory region and generation of DSCR1(e4)/lacZ
transgenic mice
DSCR1 exon 4 upstream sequence (696 to 56) was
amplified from mouse genomic DNA by PCR using primers
5V-GCCCTGCAACTACAGAAGG-3Vand 5V-GGCTT-
GGCTTCCAGAGCGTCC-3V. The sequence was verified
and linked to the basal promoter hsp68/lacZ reporter gene
(Kothary et al., 1989) to produce the DSCR1(e4)/lacZ trans-
gene. The DSCR1(e4)/lacZ transgene was isolated away
from plasmid sequence and used for pronuclear microinjec-
tions by the Cincinnati Children’s Transgenic Animal Core
Facility. Founder animals were identified by PCR amplifi-
cation of the lacZ transgene (Colbert et al., 1997). Three
separate FVBN founder lines of DSCR1(e4)/lacZ transgenic
mice with similar patterns of expression were used in the
analyses.
Genotyping and karyotyping
DSCR1(e4)/lacZ transgenic embryos were identified by
PCR analysis of yolk sac DNA using primers that recognize
the lacZ transgene (Colbert et al., 1997). NFATc1 heterozy-
gous mutant mice were obtained from Dr. Laurie Glimcher
(Ranger et al., 1998). Genotyping for NFATc1 mutation was
performed by PCR using primers designed for the wild type
and targeted alleles as described in Ranger et al. (1998).
Ts16 embryos were generated by crossing Rb(6.16)24Lub/
Rb(16.17)7BnrF1 males (obtained through the NIH/NICHD
cytogenetic models resource maintained by Jackson Labs)
with nontransgenic FVBN or DSCR1(e4)/lacZ transgenic
females. Ts16 embryos were identified by standard karyo-
type analysis of chromosomes isolated from embryonic yolk
sacs taken before E13 or from liver cells of later stage
embryos (Waller et al., 2000; Webb et al., 1996). Giemsa-
stained metaphase spreads were examined for the presence
of metacentric chromosomes indicative of Robertsonian
translocations, and trisomic embryos were identified by
the presence of two metacentric chromosomes (Epstein
and Vekemans, 1990).
Analysis of transgene expression
LacZ expression in E9.5–E14.5 embryos was analyzed
by X-gal detection of h-galactosidase (h-gal) activity as
previously described (Searcy et al., 1998). h-gal activity
was quantified in cell lysates of whole hearts from E13.5
transgenic embryos. Dissected hearts were placed in 60
Al of Tropix lysis buffer containing 0.5 mM DTT for
sonication, and h-gal activity in lysates was determined as
previously described (Liberatore et al., 2002). For histol-
ogy of X-gal stained embryos, individual hearts and heads
were infiltrated in sucrose and embedded in OCT (Stern,
Fig. 1. DSCR1 is expressed during cardiac valvuloseptal development.
DSCR1 expression in the developing heart was assessed in whole embryos
(A), bisected hearts (B), or 14-Am sections (C–F). (A) At E10.5, DSCR1 is
expressed in the outflow tract and atrioventricular canal of the developing
heart (arrows). (B) At E12.5, DSCR1 is present in the developing mitral and
tricuspid valves (arrows) as well as the surrounding atrioventricular canal
(black arrowhead) and the muscular interventricular septum (white
arrowhead). (C–F) Transverse sections of E13.5 embryos. (C) DSCR1 is
strongly expressed in the muscular interventricular septum and ventricular
myocardium of the heart as well as the dorsal root ganglion (arrowhead)
and ventral neural tube (arrow). (D) Increased magnification of boxed area
in C reveals DSCR1 expression in the endocardium of the developing mitral
and tricuspid valves (arrows). (E–F) DSCR1 is also expressed in the
endocardium of the developing aortic valves (F, arrowheads). (F) Increased
magnification of boxed area in E. ot, outflow tract; avc, atrioventricular
canal; tv, tricuspid valve; mv, mitral valve; ivs, interventricular septum,
AoV, aortic valve.
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Superfrost/Plus slides and cover slips were mounted with
50% glycerol/PBS. Images were obtained using an Olym-
pus BX60 microscope with a Spot 3.0.4 digital camera.
In situ hybridization
Embryos were isolated at E8.5–E13.5 and fixed over-
night at 4jC in 4% paraformaldehyde/PBS. For whole
mount in situ hybridization, fixed embryos were dehy-
drated in a graded methanol/PTW (PBS, 0.01% Tween-20)
series and stored at 20jC in 100% methanol. Whole
mount in situ hybridizations were performed as described
by Wilkinson (1993) with reported modifications (Ehrman
and Yutzey, 1999). E12.5–E14.5 hearts were bisected with
a razor blade before hybridization to visualize the devel-
oping valves and septa. ProteinaseK digestions were per-
formed for 10–15 min and color reactions were incubated
2 h to overnight using NBT/BCIP (Roche). Embryos used
for in situ hybridization of histological sections were
stored in PBS at 4jC following fixation and subsequently
infiltrated in sucrose and embedded in OCT (Stern, 1993).
Cryostat sections (14 Am) were place on Superfrost/Plus
slides, and non-radioactive in situ hybridization was per-
formed as described by Toresson et al. (1999). Color
reactions were carried out using BM Purple AP substrate
(Roche) for 16–72 h and cover slips were mounted with
50% glycerol/PBS.
Digoxigenin UTP-labeled antisense RNA probes were
generated for mouse DSCR1/MCIP1 and NFATc1. A
mouse DSCR1 cDNA probe (nt 404–2055) was isolated
by RT-PCR of E10.5 head RNA based on published
sequence (GenBank #AF260717) (Casas et al., 2001).
Primers for DSCR1 amplification were 5V-AGACC-
CAAGCCCAAAATCATCC-3V and 5V-TAGCCTCTC-
CGGTTCAAAGTGC-3V. The PCR-generated DNA
fragment was subcloned into pGEMT-vector (Promega),
verified by sequencing and used to generate DSCR1
antisense probe with T7 polymerase after linearization
with Not1. Alternatively embryos were hybridized with
antisense probe for mouse MCIP1 (GenBank #AF237790)
coding sequence (597 bp) initiated from exon 4 (Roth-
ermel et al., 2000). MCIP1 coding sequence (provided by
Dr. R.S. Williams, Duke University) was inserted into
pBluescript and used for probe synthesis by T7 polymerase
after linearization of plasmid with Xba1. The separate
DSCR1 and MCIP1 probes contain overlapping sequences,
had similar expression patterns, and were used inter-
changeably. Mouse NFATc1 (GenBank #AF239169) se-
quence (nt. 1313 – 2459) was isolated from E14.5
ventricular cDNA using primers 5V-GCTGTTCATTGG-
GACGGCTGACGA-3V and 5V-CACGTCACCAGGGGA-
CAGCATTAT-3V and subcloned into pBluescript. The
resulting plasmid was verified by sequencing and linear-
ized with Not1 for generation of NFATc1 antisense RNA
probe with T7 polymerase.Immunohistochemistry
Localized protein expression of NFATc1 and h-gal in
developing hearts of DSCR1(e4)/lacZ transgenic embryos
was examined by immunohistochemistry and confocal
microscopy. DSCR1(e4)/lacZ transgenic embryos were
isolated at E10.5–E13.5, fixed overnight in 4% parafor-
maldehyde/PBS at 4jC, and processed for cryosectioning
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then blocked for 30 min in 10% normal goat serum
(Sigma) in PBS and incubated with a rabbit polyclonal
anti-h-galactosidase primary antibody (1:250, Eppendorf 5
Prime, Inc.) for 30 min in blocking serum. After three
washes in PBS, sections were incubated with Alexa Fluor
488 goat anti-rabbit secondary antibody (1:100 in PBS,
Molecular Probes) for 15 min and washed three times in
PBS. Subsequently, immunolabeling for NFATc1 was per-
formed using the Vector M.O.M. Basic immunodetection
kit for detecting mouse primary antibodies on mouse tissue
according to the manufacturer’s recommendations (Vector
Labs). Briefly, sections were blocked for 1 h, then incu-
bated with mouse monoclonal anti-NFATc1 (7A6) (1:100,
Santa Cruz Biotechnology, Inc.) for 1 h in M.O.M. diluent
solution, washed in PBS, and incubated with Alexa Fluor
568 goat anti-mouse IgG (1:100 in PBS, Molecular
Probes) for 15 min. After immunofluorescent doubleFig. 2. The mouse DSCR1 exon 4 regulatory sequence contains multiple conser
DSCR1 exon 4 intragenic regulatory sequence (696 to 56) homologous to the h
mouse DSCR1(e4) regulatory region contains 10 NFAT consensus binding sequen
al., 1997). Nucleotides conserved with human DSCR1 NFAT and AP-1 consensus
al., 2000). (B) Schematic representation of the mouse DSCR1 gene comprised of
linked to the hsp68-lacZ reporter gene (Kothary et al., 1989) to generate the DSClabeling, sections were washed several times in PBS and
cover slips were mounted with Vectashield Hard Set
mounting medium (Vector Labs). Fluorescent microscopic
analysis was performed using a Nikon PCM 2000 confocal
microscope and images were obtained using SimplePCI
software.
Cell culture and transient transfections
C2C12 myoblasts were cultured in DMEM (Cellgro)
supplemented with 15% FBS, pen/strep (Gibco, 100 units/
ml), and L-glutamine (Gibco, 100 Ag/ml). Expression
vectors for wild-type and constitutively active Nfatc1
(wt-Nfatc1 and ca-Nfatc1, respectively) and pBJ5 have
been previously described (Beals et al., 1997; Porter et
al., 2000). The approximately 600 bp DSCR1(e4) intra-
genic element was ligated into the Kpn1 site of the pGL3-
Promoter vector (Promega) to generate the DSCR1(e4)-ved NFAT consensus binding sequences. (A) The sequence of the mouse
uman DSCR1/MCIP1 calcineurin response element (Yang et al., 2000). The
ces (blue) and a conserved AP-1 consensus binding sequence (red) (Rao et
binding sequences in the same positions are underscored with stars (Yang et
7 exons. The mouse DSCR1 sequence 696 to 56 relative to exon 4 was
R1(e4)/lacZ transgene.
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with 0.3 Ag of reporter plasmid and 0.1 Ag of expression
vector using FuGENE 6 Transfection Reagent (Roche). All
transfections included 0.01 Ag of pRL-TK (Promega) as an
internal control for transfection efficiency. Cells were
harvested 36–48 h after transfection and reporter activity
was measured according to protocols for the Dual Lucif-
erase Assay system (Promega) using a Monolight 3010
luminometer. Experiments were repeated three times in
triplicate and statistical significance was determined by
Student’s t test.
Quantitative real time PCR
The AVendocardial cushions and OTwere dissected from
E12.5 hearts of embryos from Nfatc1+/ matings and totalFig. 3. Cardiac expression of DSCR1(e4)/lacZ is dependent on NFATc1. (A–D)
developing heart. (A, C) Cryosections (10 Am) of DSCR1(e4)/lacZ transgenic
endocardium of the developing mitral and tricuspid valves of an E13.5 transgenic h
endothelium of the developing aortic valve of an E12.5 transgenic heart (arrowhead
NFATc1 is expressed in the endocardium of the developing mitral and tricuspid va
lacZ expression in the developing mitral valve is lost in NFATc1/ embryonic hear
heart stained with X-gal shows normal transgene expression in the developing mit
E12.5 DSCR1(e4)/lacZ;NFATc1/ heart stained with X-gal (arrow).RNA was isolated using TRIZOL (Life Technologies)
according to the manufacturer’s instructions. cDNA generat-
ed with oligo(dT) primers and the SuperScript First-Strand
Synthesis kit (Invitrogen) was used for quantitative real-time
RT-PCR using the MJ Research Opticon Monitor II system
(95jC, 30 s; 52jC, 30 s; 72jC, 30 s; 35 cycles). Reactions
included 0.1 Sybr Green (Molecular Probes) and fluores-
cence was monitored at 80jC. Primers for specific DSCR1
splice isoforms were: DSCR1(e1) 5V-ATGGAGGAGGTG-
GATCTGC-3Vand 5V-TTTATCCGGACACGTTTGAAG-3V;
DSCR1(e4) 5V-GTGTGGCAAACGATGATGTC-3V and 5V-
AGGAACTCGGTCTTGTGCAG-3V. Gene expression lev-
els were quantified based on the threshold cycle [C(t)]
calibrated to a standard curve generated using E14.5 whole
heart cDNA and normalized to h-actin (Broberg et al., 2003).
Reactions were repeated twice using technical duplicatesDSCR1(e4)/lacZ is expressed in a subset of NFATc1-expressing cells in the
mouse hearts stained with X-gal. (A) h-galactosidase is detected in the
eart (arrowheads). (C) DSCR1(e4)/lacZ is also expressed in the endocardial
s). (B, D) In situ hybridization of histological sections (14 Am) for NFATc1.
lves (B) as well as the developing pulmonary valve (D). (E–F) DSCR1(e4)/
ts. (E) Histological section (10 Am) of an E12.5 DSCR1(e4)/lacZ;NFATc1+/+
ral valve (arrow). (F) h-gal activity is not detected in the mitral valve of an
A.W. Lange et al. / Developmental Biology 266 (2004) 346–360 351from three independent samples of each genotype and statis-
tical significance was determined using Student’s t test.Results
DSCR1 is expressed in the developing valves and septa of
the heart
The expression of the Down syndrome candidate gene
DSCR1 was examined during embryonic heart formation
in the mouse. Previous studies demonstrated that DSCR1
is expressed in the developing mouse heart at E9.5 to
E10.5 but expression during valvuloseptal development
was not reported (Casas et al., 2001; Vega et al., 2003).
A more complete analysis of DSCR1 expression was
obtained by in situ hybridization of whole mount and
sectioned embryos. DSCR1 is expressed in the developing
mouse heart as early as E8.5 (data not shown). At E10.5,
DSCR1 expression is detected in the outflow tract (OT)
and atrioventricular canal (AVC) where the endocardial
cushions are induced (Fig. 1A). These structures later
contribute to the valves and septa of the heart as it
divides into four chambers. In bisected E12.5 hearts,
DSCR1 expression is apparent in the muscular interven-
tricular septum (IVS) and AVC myocardium in additionFig. 4. DSCR1(e4)/lacZ transgene expression colocalizes with NFATc1 in the d
localization was examined by fluorescent confocal microscopy on E11.5 DSC
embryonic outflow tract. (D–F) Atrioventricular endocardial cushions. Arrowh
NFATc1 and h-gal. Note that only a subset of endocardial valve cells that expresto the developing AV valves (Fig. 1B). In sectioned
E13.5 embryos, DSCR1 expression in the heart is
detected throughout the ventricular myocardium but is
enriched in the muscular IVS (Figs. 1C–E). DSCR1
expression is also apparent in the dorsal root ganglion
and ventral portion of the neural tube (Fig. 1C). In the
developing valves, DSCR1 gene expression is restricted
to the endocardial cells (Figs. 1C–F). Thus, DSCR1
expression in the embryonic heart, notably in the ven-
tricular septum, AV canal, and developing valve endo-
cardium, is consistent with a role in valvuloseptal
formation.
Expression of DSCR1(e4) in the developing valve
endocardium is dependent on NFATc1
Human DSCR1 contains an intragenic promoter adjacent
to exon 4 that is responsive to calcineurin signaling via
clustered NFAT consensus-binding sequences (Yang et al.,
2000). A homologous sequence in mouse DSCR1 was
identified after isolation of the gene. Sequence analysis of
the region 5V to exon 4 in mouse and human DSCR1 shows
a high degree of homology between the murine sequence
and the human DSCR1/MCIP1 intragenic calcineurin-re-
sponsive promoter. The approximately 700 bp adjacent to
mouse DSCR1 exon 4 contains 10 NFAT-binding sites basedeveloping valve endocardium. NFATc1 (red) and h-galactosidase (green)
R1(e4)/lacZ transgenic hearts. (A–C) Valvuloseptal endocardium of the
eads denote endothelial endocardial cells with colocalized expression of
s NFATc1 (arrows, D and F) have colocalized h-gal expression.
Fig. 5. DSCR1(e4) expression is responsive to NFATc1 through the
intragenic promoter. (A) Endogenous DSCR1 transcript expression in the
OT of Nfatc1 mutant hearts. Expression levels of DSCR1(e1) and
DSCR1(e4) in isolated OT were measured by quantitative real-time RT-
PCR using primers for specific alternative transcripts. Expression levels of
calcineurin-insensitive DSCR1(e1) are maintained despite loss of NFATc1,
but NFATc1 deficiency results in decreased expression of the calcineurin-
responsive DSCR1(e4) isoform. DSCR1(e4) levels quantified in the
experiments were consistently less abundant (approximately .19X) than
DSCR1(e1) expression levels. Reactions were repeated twice using three
independent samples from each genotype, and expression levels were
quantified in relation to a standard curve and normalization to h-actin.
Graphs represent the average fold change in expression relative to
Nfatc1+/+ F the standard deviation. (B) Transient transfection assays.
C2C12 myoblasts were transfected with the DSCR1(e4)-luciferase reporter
in combination with pBJ5 control vector, wt-Nfatc1, or ca-Nfatc1 expression
vectors. The reporter plasmid is activated by wt-Nfatc1 (5.01 fold F1.43)
and ca-Nfatc1 (8.02 fold F3.54) in comparison to basal expression with the
vector control. The graph represents the average fold activation F the
standard deviation from three independent transfections performed in
triplicate. Asterisks represent statistical significance as determined by
Student’s t test ( P < 0.05).
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(Rao et al., 1997; Yang et al., 2000). Eight of these sites are
100% conserved with the human sequence and an additional
pair of NFAT sites at 572 to 556 is unique to the mouse
DSCR1(e4) element. In addition to the NFAT sites, a
conserved consensus binding sequence for AP-1, a known
NFAT cofactor, is present adjacent to an NFAT site (104 to
91) in the mouse DSCR1(e4) regulatory element and both
of these sites are 100% conserved in the human sequence
(Macian et al., 2001; Yang et al., 2000). NFATs also can
function with GATA or MEF-2 transcription factors but no
GATA/NFAT or MEF-2/NFAT consensus binding sequences
are present in the DSCR1(e4) NFAT-rich regulatory se-
quence (Molkentin et al., 1998; Nemer and Nemer, 2002;
Wu et al., 2000). The high degree of homology and
conservation of NFAT consensus binding sequences be-
tween the mouse and human DSCR1(e4) sequence is evi-
dence for conserved calcineurin-sensitive regulation of
DSCR1 gene expression through activated NFATs (Yang et
al., 2000).
The embryonic expression of mouse DSCR1 via the
NFAT-rich regulatory sequence adjacent to exon 4 was
examined in transgenic mice in which the DSCR1(e4)
regulatory sequence (696 to 56 relative to exon 4) was
linked to the hsp68/lacZ reporter gene (Fig. 2B). Whole
mount X-gal staining of transgenic embryonic hearts for h-
galactosidase activity revealed DSCR1(e4)/lacZ transgene
expression in the developing OT and AV valves of the
embryonic heart (Fig. 3). Similar cardiac expression of
DSCR1(e4)/lacZ was observed for three independent trans-
genic lines. Transgene expression in the OT is detected as
early as E9.5, and DSCR1(e4)/lacZ is expressed in the
endothelial cell layer of the OT endocardial cushions and
aorticopulmonary septum at E11.5–E12.5 (data not shown).
During endocardial cushion remodeling and valve leaflet
maturation (E13.5–E15.5), DSCR1(e4)/lacZ is expressed in
a subset of endocardial cells in the developing AV and
semilunar valves (Figs. 3A, C). Although DSCR1(e4)/lacZ
is expressed in both nascent AV valves between E12.5 and
E14.5, predominant expression is observed in the develop-
ing mitral valve (Figs. 3A, E). DSCR1(e4)/lacZ expression
was down-regulated after E14.5 and no expression was
observed in the adult heart (data not shown). Unlike
endogenous DSCR1, expression of the DSCR1(e4)/lacZ
transgene is not apparent in the ventricular myocardium
and was only rarely observed in the IVS in a punctate
manner (data not shown). Thus, the cardiac expression of
the DSCR1(e4)/lacZ transgene recapitulates a specific sub-
domain of embryonic expression of endogenous DSCR1.
Expression of DSCR1(e4)/lacZ in the developing heart
valves is similar to expression of NFATc1, which is required
for normal valvuloseptal formation (de la Pompa et al.,
1998; Ranger et al., 1998). NFATc1 is expressed in the
endocardium of the AV and semilunar valve primordia at
E13.5 (Figs. 3B, D). Comparison to DSCR1(e4)/lacZ ex-
pression reveals that the transgene is expressed in the samecell layer as NFATc1 in corresponding cardiac structures.
Interestingly, NFATc1 expression is not apparent in the
muscular ventricular septum or ventricular myocardium.
Thus, DSCR1 and NFATc1 expression overlap in the endo-
thelium of the developing AV and semilunar valves, but
DSCR1 alone is expressed in the developing muscular
ventricular septum and ventricular myocardium. Therefore,
the DSCR1 expression subdomain revealed by DSCR1(e4)/
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regulated by activated NFATc1.
To determine the dependence of DSCR1(e4)/lacZ expres-
sion on NFATc1 function in the developing heart,
DSCR1(e4)/lacZ transgenic mice were crossed with NFATc1
mutant mice (Ranger et al., 1998). NFATc1 mutant embryos
carrying the DSCR1(e4)/lacZ transgene were examined at
E12.5 when the AV valve primordia are apparent and the
NFATc1/ embryos are still viable. In DSCR1(e4)/lacZ;
NFATc1+/+ embryos, the transgene is expressed predomi-
nantly in the developing mitral valve (Fig. 3E). However,
mitral valve expression of DSCR1(e4)/lacZ is visibly re-
duced or absent in transgenic embryos that are null for
NFATc1 (Fig. 3F). The loss of DSCR1(e4)/lacZ transgene
expression is not due to absence of the endocardium in
NFATc1/ embryos, as determined by PECAM-1 staining
of endothelial cells (de la Pompa et al., 1998). In addition,
DSCR1(e4)/lacZ expression was not observed in the severe-
ly hypomorphic semilunar valves of NFATc1/ embryos
(data not shown) (de la Pompa et al., 1998; Ranger et al.,
1998). The overlapping expression of NFATc1 and
DSCR1(e4)/lacZ suggests that NFATc1 may contribute toFig. 6. DSCR1(e4)/lacZ is expressed in developing organs affected in Down syndro
E13.5, and h-gal activity was detected by overnight X-gal staining. Expression
phenotypic traits including the eye (arrow, E), ear (arrowhead, E), pharyngeal arc
(arrow, A). (C, F) E11.5 DSCR1(e4)/lacZ;Nfatc1/ embryos exhibited transgene
littermates with apparent decreased expression in the face (arrowheads) and ear (the activation of transgene expression in the developing
valve endocardium.
The colocalization of NFATc1 and DSCR1(e4)/lacZ
transgene expression in the embryonic valve endocardium
was confirmed by confocal microscopy. Double-labeled
immunofluorescence for NFATc1 and h-galactosidase pro-
tein was performed on sections from E11.5 DSCR1(e4)/lacZ
transgenic embryos. NFATc1 is detected in the endocardial
cells of the OT and AV valvuloseptal primordia, which is
consistent with the observed gene expression pattern (Figs.
4A, D). Likewise, h-gal expression is restricted to the
developing OT and AV valvuloseptal endocardium (Figs.
4B, E), and transgenic h-gal specifically colocalizes with a
subset of NFATc1-expressing cells (Figs. 4C, F). The
coincident expression of NFATc1 and h-gal in the primitive
valves and dependence of DSCR1(e4)/lacZ expression on
NFATc1 is consistent with regulation of DSCR1 gene
expression in the developing valve endocardium by NFATc1
through the NFAT-rich regulatory sequences.
The potential direct regulatory interaction between
NFATc1 and DSCR1 gene expression controlled by the
intragenic promoter element was examined in mutant miceme and in NFATc1 null embryos. Embryos were analyzed between E9.5 and
is detected in developing organ systems associated with Down syndrome
hes (black arrow, B), brain (white arrow, B), limbs (arrows, D), and heart
expression in developing organs comparable to DSCR1(e4)/lacZ;Nfatc1+/+
arrows).
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respectively. The dependence of the endogenous DSCR1
intragenic promoter on NFATc1 was examined by quan-
titative real-time RT-PCR analysis of DSCR(e1) and
DSCR1(e4) expression in Nfatc1 gene targeted mice. In
cultured cells and adult hearts, DSCR1(e4) expression is
responsive to calcineurin signaling, whereas expression of
the DSCR1(e1) splice variant is insensitive to such stimuli
(Yang et al., 2000). Endogenous DSCR1(e4) vs. (e1)
transcript levels were examined in OT of Nfatc1 mutant
mice, with major defects in semilunar valve formation (de
la Pompa et al., 1998; Ranger et al., 1998). DSCR1(e4)
expression levels were significantly reduced in Nfatc1/
OT in comparison to OT from Nfatc1+/+ hearts (Fig. 5A).
DSCR1(e4) expression is also decreased in Nfatc1+/ OTs,
but the reduction is not statistically significant in comparison
to Nfatc1+/+ levels (Fig. 5A). In contrast, DSCR1(e1) ex-
pression is relatively unaffected by loss of NFATc1 (Fig.
5A). These results are consistent with previous reports of
differential gene regulation of DSCR1(e1) and DSCR1(e4)
isoforms in response to calcineurin/NFAT signaling. The
ability of NFATc1 to trans-activate theDSCR1(e4) regulatory
element also was assessed in transfected C2C12 myogenic
cells. The approximately 600 bp DSCR1(e4) intragenic
sequence was cloned into a luciferase vector to generate a
DSCR1(e4)-luciferase reporter construct. In co-transfection
assays, theDSCR1(e4) regulatory element is activated by wt-
NFATc1 (5.01 F 1.43-fold) and constitutively active (ca)-
NFATc1 (8.02 F 3.54-fold) in comparison to the control
vector (Fig. 5B). These data provide further evidence for
direct gene regulation. Together, these results demonstrate
that in vivo and cell culture expression of the calcineurin-
sensitive DSCR1(e4) isoform, but not DSCR1(e1), is depen-Fig. 7. Cardiac expression of endogenous DSCR1 and transgenic
DSCR1(e4)/lacZ colocalizes with anomalous development of Ts16 hearts.
(A, C, E, G) Disomic embryonic hearts. (B, D, F, H) Trisomy 16 embryonic
hearts. (A–D) In situ hybridization for DSCR1 was performed on bisected
E12.5 (A, B) and cryosectioned (14 Am) E13.5 (C, D) hearts from
intercrosses between Rb(6.16)24Lub/Rb(16.17)7BnrF1 males and non-
transgenic females. Endogenous DSCR1 gene expression is detected in the
interventricular septum (arrowheads, A–D) and endothelium of the
developing endocardial cushions/valves (ec) (arrows, B–D) in both
disomic and trisomic hearts. (D) Note the abnormal atrioventricular
endocardial cushions and malalignment of the ventricular septum (asterisk)
in correlation with DSCR1 expression in the heart of a Ts16 embryo. (E–H)
Cryosections (10 Am) of X-gal stained hearts stained from intercrosses
between Rb(6.16)24Lub/Rb(16.17)7BnrF1 males and DSCR1(e4)/lacZ
transgenic females. (E) At E12.5, a DSCR1(e4)/lacZ;Ds16 heart has normal
transgene expression in the developing mitral valve (arrow). (F) h-gal is
detected in the abnormally developing atrioventricular endocardial cushions
of an E12.5 DSCR1(e4)/lacZ;Ts16 heart (arrows). (G) By E14.5, transgene
expression is reduced in the maturing mitral and tricuspid valves of a
DSCR1(e4)/lacZ;Ds16 heart (arrows). (H) h-gal activity persists in the
malaligned endocardial cushions of an E14.5 DSCR1(e4)/lacZ;Ts16 heart
with delayed valvuloseptal development. Quantitative assays reveal average
h-gal activity in E13.5 DSCR1(e4)/lacZ;Ts16 whole hearts (n = 5) is
approximately 2.5 greater than in DSCR1(e4)/lacZ;Ds16 hearts (n = 13).dent on NFATc1 through a conserved intragenic promoter
containing multiple consensus NFAT sites.
DSCR1(e4)/lacZ is expressed in developing organs affected
in human Down syndrome and mouse trisomy 16
DSCR1(e4)/lacZ transgenic embryos were examined for
developmental expression in organ systems other than the
heart by whole mount X-gal staining. Transgene expression
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and at E9.5 in the outflow tract of the heart, consistent with
the onset of endogenous DSCR1 expression (data not shown
and Fig. 6A). Between E10.5 and E13.5 DSCR1(e4)/lacZ is
expressed in several developing craniofacial structures in-
cluding the brain, eye, pharyngeal arches, and ear (Fig. 6).
Transgene expression is also apparent in the condensing
cartilage of the developing limbs (Fig. 6D). Whole mount
DSCR1(e4)/lacZ expression in Nfatc1/ embryos carrying
the transgene was also examined to assess if transgene
expression was altered in any developing organs other than
the heart. Expression of the transgene outside of the heart is
detected, but apparently reduced in some structures, includ-
ing the face and ear, of DSCR1(e4)/lacZ;Nfatc1/ embryos
in comparison to DSCR1(e4)/lacZ;Nfatc1+/+ littermates
(Figs. 6C, F). Together, these results show that embryonic
DSCR1(e4)/lacZ expression is regulated by complex
NFATc1-dependent and independent mechanisms and that
the embryonic organ systems expressing in DSCR1(e4)/lacZ
correlate with the most prevalent developmental anomalies
characteristic of human Down syndrome.
The expression of endogenous DSCR1 and the
DSCR1(e4)/lacZ transgene were examined in Ts16 mouse
embryos to assess gene expression in embryonic structuresFig. 8. DSCR1(e4)/lacZ is expressed in abnormally developing structures of
Rb(6.16)24Lub/Rb(16.17)7BnrF1 males and h-galactosidase expression was de
expression in an E14.5 disomic embryo. (B) In comparison, DSCR1(e4)/lacZ trans
face (asterisks), neural tube (white arrow), limbs (black arrowheads), and cranial str
Am) of E14.5 heads stained with X-gal. DSCR1(e4)/lacZ is expressed in the neura
and trisomic (D) embryos. (E–F) h-gal is detected in the developing skull (sk, arro
DSCR1(e4)/lacZ expression is reduced during abnormal skull development in Ts1ultimately affected in human Down syndrome. Progeny of
male mice bearing metacentric Robertsonian chromosome
6/16 and 16/17 fusions (Rb(6.16)24Lub/Rb(16.17)7BnrF1)
are trisomic for chromosome 16, have developmental
anomalies, and do not survive to birth (Epstein and Veke-
mans, 1990; Epstein et al., 1985; Miyabara et al., 1982).
Rb(6.16)24Lub/Rb(16.17)7BnrF1 male mice were bred with
euploid nontransgenic or DSCR1(e4)/lacZ females to pro-
duce litters with a Mendelian ratio of 1/4 embryos with
trisomy 16. Embryos were examined at E12.5–E14.5 and
Ts16 embryos were confirmed by karyotype analysis. Sev-
eral obvious morphological defects are apparent in the Ts16
embryos beginning at E12.5 including edema, delayed rib
cage development, abnormal head formation, and small
stature.
Endogenous DSCR1 gene expression was examined in
Ts16 and Disomy 16 (Ds16) hearts by in situ hybridization.
DSCR1 is expressed in the IVS, AVC, ventricular myocar-
dium, and the AV endocardial cushion endothelium of
E12.5–E13.5 disomic and trisomic embryo hearts (Figs.
7A–D). Expression regulated by the DSCR1(e4) NFAT-rich
regulatory element was also evaluated in Ts16 embryos with
congenital heart malformations. Like endogenous DSCR1,
the DSCR1(e4)/lacZ transgene is expressed in endocardialTs16 embryos. DSCR1(e4)/lacZ transgenic females were crossed with
tected by X-gal staining. (A) Whole mount DSCR1(e4)/lacZ transgene
gene expression is reduced in the abnormally developing eye (black arrow),
uctures (white arrowheads) of a trisomic littermate. (C–F) Cryosections (25
l retina (re, arrows) and near the eyelid (e, arrowheads) in both disomic (C)
ws) and striatum (st, arrowheads) of disomic (E) and trisomic (F) embryos.
6 embryos (F, arrowhead).
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embryos (Fig. 7). The abnormally developing endocardial
cushions and malalignment of the interventricular septum
are evident in the Ts16 hearts and these structures express
DSCR1(e4)/lacZ and/or endogenous DSCR1, supporting the
association between DSCR1 expression and abnormal de-
velopment of valve and septal precursors (Figs. 7B, D, F,
H). At E14.5, DSCR1(e4)/lacZ transgene expression
remains strong in abnormal malaligned endocardial cush-
ions of the Ts16 hearts but is down-regulated in the
maturing AV valves of the normal Ds16 hearts (Figs. 7G,
H). Analysis of transgene expression levels by quantitative
h-gal enzymatic assay reveals approximately 2.5-fold more
h-gal activity in Ts16 whole hearts compared to Ds16 hearts
(data not shown). The increased transgene expression in the
Ts16 hearts could be due to altered NFAT activity, but also
may be the result of delayed transgene down-regulation due
to abnormal valve maturation and cushion remodeling pro-
cesses in these embryos. Together, the expression of endog-
enous DSCR1 and DSCR1(e4)/lacZ correlates with regions
of the heart undergoing anomalous valvuloseptal develop-
ment in Ts16 embryos.
DSCR1(e4)/lacZ expression was examined in other de-
veloping organ systems affected in Ts16 embryos (Fig. 8).
In Ts16 embryos, DSCR1(e4)/lacZ expression in the poste-
rior neural tube, eye, and face is reduced and expression in
the developing skull appears abnormal relative to Ds16
embryos (Figs. 8A, B). Reduced h-gal expression is appar-
ent on the surface of the face near the eyelids and nasal
structures of trisomic embryos in comparison to disomic
littermates (Figs. 8A, B, indicated by asterisks). Frozen
sections (25 Am) of E14.5 heads revealed transgene expres-
sion in the neural retina of the developing eye in both
disomic and trisomic embryos (Figs. 8C, D). DSCR1(e4)/
lacZ expression in the inner surface of the retinal epithelium
is consistent with expression of endogenous DSCR1 in the
developing eye (data not shown). However, where endog-
enous DSCR1 is also strongly expressed throughout the
developing lens, the DSCR1(e4)/lacZ transgene only shows
punctate expression in this region (Figs. 8C, D and data not
shown). Transgene expression in Ts16 embryos also is more
diffuse in the developing skull and is apparent in the
developing striatum of the forebrain (Figs. 8A, B, E, F).
DSCR1(e4)/lacZ transgene expression observed in the de-
veloping striatum is consistent with reports of endogenous
DSCR1 gene expression in the embryonic and postnatal
forebrain (Casas et al., 2001). Thus, DSCR1(e4)/lacZ is
expressed in several embryonic organ systems with devel-
opmental anomalies that result from trisomy 16 in mice.Discussion
The regulation of DSCR1 gene expression was examined
at critical stages of normal valvuloseptal development as
well as in mice with cardiac malformations resulting fromNFATc1 deficiency or Ts16. DSCR1 is expressed in devel-
oping valvuloseptal structures in the embryonic heart in-
cluding the AVand semilunar valve primordia as well as the
interventricular septum and AV canal myocardium. In
transgenic mice, conserved DSCR1 intragenic NFAT-rich
regulatory sequences control lacZ transgene expression in
several embryonic organ systems affected in Down syn-
drome. In the developing heart, DSCR1(e4)/lacZ transgene
expression colocalizes with NFATc1 in the endothelial layer
of the valve primordia and the DSCR1(e4) intragenic
promoter is activated by NFATc1 in vitro. In addition,
expression of endogenous DSCR1(e4) and DSCR1(e4)/lacZ
is affected in NFATc1/ hearts that exhibit valvuloseptal
maturation defects, further supporting the regulation of
DSCR1(e4) gene expression in the valvuloseptal endocardi-
um by activated NFATs. Expression of endogenous DSCR1
and the DSCR1(e4)/lacZ transgene is also observed in
several embryonic structures that develop abnormally in
Ts16 mice. Together, these results provide evidence for
DSCR1 as a target gene for NFATc1 in valvuloseptal
development and support a role for trisomic DSCR1 in
Down syndrome-related developmental anomalies.
DSCR1(e4) expression is dependent on NFATc1 during
valvuloseptal development
The expression of endogenous DSCR1 and the
DSCR1(e4)/lacZ transgene in the developing heart is con-
sistent with a role in valvuloseptal formation. The onset of
DSCR1 expression in the OT and AV junction of the heart at
E9.5 is concurrent with the initiation of endocardial cushion
formation. In the endocardial cushions, expression of both
DSCR1 and DSCR1(e4)/lacZ is limited to the endothelial
cell layer and is not observed in the cushion mesenchyme.
Notably, where DSCR1(e4)/lacZ expression in the heart is
limited to the endocardium of the valvuloseptal precursors,
endogenous DSCR1 expression is also apparent in the
ventricular myocardium and muscular IVS. The non-over-
lapping regions of DSCR1(e4)/lacZ and endogenous DSCR1
gene expression in the developing heart may represent
expression regulated by other DSCR1 promoters, expression
regulated by additional intragenic regulatory sequences
outside of the DSCR1(e4) proximal 700 bp, or expression
of alternative DSCR1 splice isoforms. Transcripts originat-
ing from exon 1 and exon 4 of human DSCR1 are coex-
pressed in several adult tissues including the brain and heart,
and selective induction of DSCR1(e4) vs. DSCR1(e1) has
been demonstrated in transgenic mice expressing constitu-
tively active calcineurin in the heart (Ermak et al., 2002;
Fuentes et al., 1997; Yang et al., 2000). Therefore, differ-
ential expression of mouse DSCR1 isoforms in the devel-
oping heart could also be regulated by multiple promoters.
Both endogenous DSCR1 and DSCR1(e4)/lacZ are
expressed in the endothelial cell layer with NFATc1 in the
AV and semilunar valve primordia during valvuloseptal
maturation and remodeling. The expression of the
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in the endothelium of the valve primordia in the absence of
NFATc1. This loss of transgene expression is corroborated
by a significant decrease in endogenous DSCR1(e4) expres-
sion in the OT of Nfatc1/ hearts. Notably, DSCR1(e1)
expression was not affected in the OT of Nfatc1 mutant
hearts, supporting differential sensitivity of DSCR1 splice
variants to altered calcineurin/NFAT signaling (Yang et al.,
2000). Although the regulatory interaction between NFATc1
and the DSCR1(e4) intragenic promoter could occur by an
indirect mechanism, several lines of evidence support
DSCR1(e4) as a target gene directly regulated by NFATc1
in valvuloseptal development. These include colocalized
endocardial expression of NFATc1 and DSCR1(e4)/lacZ,
the presence of conserved NFAT consensus binding sequen-
ces in the DSCR1(e4) promoter, in vitro activation of the
DSCR1(e4) promoter by NFATc1, and loss of transgene and
endogenous DSCR1(e4) gene expression in NFATc1 mutant
hearts. Together, the temporal and spatial expression of
DSCR1 in the endocardial cushions and primitive valves
along with the dependence of DSCR1(e4) cardiac expres-
sion on NFATc1 support a role for DSCR1 in the endocar-
dium during valvuloseptal development.
The identification of transcriptional targets for NFATc1 in
the AV canal and outflow tract endocardium is in the early
stages of investigation. In this study, we show thatDSCR1 is a
likely target of NFATc1 in valvuloseptal remodeling. In
addition, NFATc1 was recently shown to cooperate with
GATA-5 to synergistically activate endothelin-1 gene expres-
sion in cultured TC-13 endothelial cells (Nemer and Nemer,
2002). Recent studies have also provided novel insights into
the signaling events that control NFATc1 activation in adult
valves as well as during valvuloseptal development. In-
creased VEGF signaling in adult human pulmonary valve
endothelial cells induces nuclear localization of activated
NFATc1 as well as cell proliferation (Johnson et al., 2003).
VEGF also has a critical role in embryonic valve maturation,
however, the potential relationship of VEGF to NFATc1
activation and function in the developing valves has not yet
been established (Carmeliet et al., 1996; Dor et al., 2001,
2003; Ferrara et al., 1996). Additionally, endothelial-specific
loss of NF1 (neurofibromatosis type 1), which encodes a ras
inhibitor, results in increased MAPK activation, premature
nuclear localization of NFATc1, and enlarged endocardial
cushions (Gitler et al., 2003; Lakkis and Epstein, 1998).
Together, these studies suggest that intersecting signal trans-
duction pathways contribute toward nuclear translocation of
NFATc1 in developing valvuloseptal structures. Investigation
of the relationship between these signaling pathways and
NFATc1 target genes in the valvuloseptal endocardium may
provide insight into the molecular mechanisms of cardiac
valve and septa development.
The function of DSCR1 in valvuloseptal development is
not known. Notably, DSCR1 is not absolutely required for
normal formation of the chambered heart as DSCR1/
mice are viable with no obvious cardiac malformations(Vega et al., 2003). However, it remains possible that other
members of the DSCR1 family of proteins (DSCR1L1/
MCIP2 and DSCR1L2/MCIP3), which are expressed in
the heart and are capable of interacting with calcineurin,
may be sufficient to functionally compensate for loss of
DSCR1 during embryonic development (Miyazaki et al.,
1996; Rothermel et al., 2000; Strippoli et al., 2000). In
addition, transgenic expression of DSCR1/MCIP1 in the
myocardium using the a-MyHC promoter is not overtly
detrimental to normal cardiac development and function, but
endothelial expression of DSCR1 was not affected in these
embryos (Rothermel et al., 2001). Currently, DSCR1 is
thought to have dual roles in regulation of calcineurin
activity. Overexpression studies of DSCR1/MCIP1 both in
vivo and in cultured cells suggest DSCR1 functions as a
feedback inhibitor of calcineurin. Analysis of DSCR1/
MCIP1/ mice, as well as loss of function mutations in
yeast or C. neoformans fungal homologues (Rcn1p and
CBP1, respectively), suggest that DSCR1 is also required
for maximal calcineurin activity under certain conditions
(Rothermel et al., 2003; Vega et al., 2003). Together, these
findings support a model in which DSCR1 proteins can
potentiate calcineurin activity, possibly by localizing calci-
neurin to the appropriate target substrates, while overex-
pression of DSCR1 may result in competition with
downstream targets for interaction with calcineurin to
effectively inhibit signal transduction (Rothermel et al.,
2003). Thus, additional experiments are necessary to ad-
dress the specific contributions of DSCR1 to the calci-
neurin/NFAT pathway during normal and abnormal
valvuloseptal development.
Developmental regulation of DSCR1 is consistent with a
role in Down syndrome-related congenital anomalies
Congenital heart defects associated with Down syndrome
include high incidence of AV septal defects, ventricular
septal defects, tetralogy of Fallot, and related valvuloseptal
abnormalities (Freeman et al., 1998). Similar defects are
seen in Ts16 mice and are attributed to cushion malalign-
ment and defects in later chamber formation (Epstein et al.,
1985; Webb et al., 1997). In this study, we report that
endogenous DSCR1 and DSCR1(e4)/lacZ are expressed in
cardiac structures affected in Ts16 embryos, supporting a
possible contribution of DSCR1 to congenital heart defects
associated with Down syndrome. The spectrum of congen-
ital anomalies associated with Down syndrome is thought to
result from disruption of normal developmental processes
by overexpression of trisomic genes (Reeves et al., 2001).
Initial evidence for increased DSCR1 expression with triso-
my of the gene locus is provided by studies of gene
expression in the brain of Down syndrome fetuses (Fuentes
et al., 2000). The levels of endogenous DSCR1 expression
in Ts16 hearts reported herein appeared higher in the AV
cushion endocardium but more quantitative methods of
evaluating gene expression are necessary to confirm that
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heart. The identification of the specific consequences of
elevated DSCR1 in valvuloseptal precursors may provide
further clues into the molecular basis of Down syndrome-
related congenital heart defects.
DSCR1 and the DSCR1(e4)/lacZ transgene are expressed
in several organ systems of the embryo affected by Ts16 in
mice and Down syndrome/Ts21 in humans. The
DSCR1(e4)/lacZ transgene expression in the pharyngeal
arches that contribute to the face is consistent with charac-
teristic facial abnormalities associated with Ts21 (Reeves et
al., 2001). Further, expression of DSCR1(e4)/lacZ in the
developing retina corresponds with vision defects common
in individuals with Down syndrome. Transgene expression
surrounding the eye is also consistent with defective eyelid
closure in Ts16 embryos, as well as characteristic upslanting
fissures and epicanthal folds associated with Down syn-
drome (da Cunha and Moreira, 1996; Lipski and Bersu,
1990). DSCR1(e4)/lacZ expression in the otic vesicle and
developing ear also correlates with Down syndrome-related
anomalies including small, malpositioned ears and conduc-
tive hearing loss (Mazzoni et al., 1994). Interestingly,
elevated expression of human DSCR1 has also been asso-
ciated with the neuropathology of Alzheimer’s disease
which is predominant in individuals with Down syndrome
(Ermak et al., 2001; Wisniewski et al., 1985). A character-
istic defect associated with these Alzheimer-like conditions
is the formation of amyloid plaques in the striatum, a region
of the forebrain that expresses DSCR1(e4)/lacZ as well as
endogenous DSCR1 (Casas et al., 2001). Together, these
observations provide a strong correlation between regions of
DSCR1 expression in the embryo and organ systems affect-
ed in Ts16 mice or individuals with Down syndrome.
DSCR1, a Down syndrome candidate gene
Based on the diversity of affected systems and variability
of the phenotype, the gene(s) responsible for Down syn-
drome-related anomalies likely will be expressed in com-
plex temporal–spatial patterns during development and may
contribute to distinct aspects of the syndrome. The calci-
neurin/NFAT signal transduction pathway has not been
previously associated with Down syndrome developmental
anomalies. However, calcineurin signal transduction has
been implicated in heart and brain development, as well
as learning and memory, and could be affected with in-
creased DSCR1 expression observed in Down syndrome
fetuses (Fuentes et al., 2000; Graef et al., 2001; Malleret et
al., 2001). The individual contribution of DSCR1 to Down
syndrome is unknown, but its embryonic expression in
regions of valvuloseptal development suggests that trisomic
DSCR1 may contribute to congenital heart defects. Further
genetic investigations examining the consequences of al-
tered copy number of the DSCR1 gene are necessary to
assess the specific contributions of trisomic DSCR1 to
Down syndrome phenotypes.Acknowledgments
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